Skip to content
Search AI Powered

Latest Stories

NICE recommends faecal immunochemical tests for colorectal cancer to reduce waiting time for colonoscopies

National Institute for Health and Care Excellence (NICE)’s diagnostic advisory committee has recommended the use of HM-JACKarc or OC-Sensor quantitative faecal immunochemical tests (FIT) in a draft guidance release for consultation on Wednesday (5 July).

Under existing NICE guidance, FIT was already offered to some people presenting to primary care with symptoms suggestive of colorectal cancer, while others were immediately referred on the suspected cancer pathway.


The new draft guidance will now see everyone receive a FIT.

A sample is sent in the post to a laboratory where the amount of blood in the faeces is measured. The results are usually available within a week and people with 10 or more micrograms of haemoglobin in their faeces should then be referred for further investigation.

Further assessment using colonoscopy, or CT colonography, is required to diagnose cancer.

The tests cost between £4 and £5 per sample, and can correctly identify about 9 out of 10 people with colorectal cancer.

The committee agreed it is important that GPs can refer people for colonoscopy without a positive FIT result if they think it is necessary and where symptoms persist.

The institute believes that the recommendation of the tests should reduce the number of unnecessary colonoscopies, thus freeing up appointments for more non-urgent referrals. This should lead to 50% fewer referrals for urgent colonoscopies being made by GPs in primary care settings each year.

There are 42,000 new cases of colorectal cancer each year according to Cancer Research UK.

Mark Chapman, interim director of medical technology and digital evaluation at NICE, said: “Colorectal cancer is the fourth most common cancer in the UK and ensuring people receive a fast diagnosis must be a priority to allow treatment to get started as soon as possible.

“We know the demand for colonoscopies is high, so recommending the use of FIT in primary care could identify people who are most likely to have a condition that would be detected by colonoscopy.

“Introducing FIT to people as an initial test will also mean that those who are unlikely to have colorectal cancer may avoid having a colonoscopy, and those who are more likely to have it can be prioritised. We hope this will reduce waiting times because fewer people will be receiving a colonoscopy they don’t need.

“These recommendations ensure we are balancing the best care with value for money, while at the same time delivering both for individuals and society as a whole.”

A consultation has now begun on the committee’s recommendations via nice.org.uk until Wednesday 19 July 2023. 

More For You

Sigma Conference: "Pharmacists need greater role in integrated care boards," says CPE representative

Prakash Patel was speaking at a panel discussion at the Sigma Conference

Sigma Conference: "Pharmacists need greater role in integrated care boards," says CPE representative

Pharmacists need to be a part of integrated care boards (ICB) to stop GPs from monopolising services based on their needs rather than the needs of the patient, according to Prakash Patel, Community Pharmacy Engaland (CPE) representative for North London.

“The evolution of the NHS should mean there can be no decision of pharmacy without pharmacist,” Patel told delegates at the Sigma Pharmacy Conference in Baku, Azerbaijan on Tuesday.

Keep ReadingShow less
David Webb
David Webb, NHS England's Chief Pharmaceutical Officer
David Webb, NHS England's Chief Pharmaceutical Officer

Sigma Conference: "Community pharmacy ready to make a profound contribution to 10 Year Health Plan," says David Webb

A national community pharmacy prescribing service remains a long-term goal of the government, according to NHS chief pharmaceutical officer, David Webb.

The Labour Party in its election manifesto last year said it would “create a Community Pharmacist Prescribing Service, granting more pharmacists independent prescribing rights”.

Keep ReadingShow less
New professional liability insurance policy for RPS members launched

The insurance will be provided to members at cost, with no profit made by RPS.

gettyimages

RPS launches professional liability insurance for members

The Royal Pharmaceutical Society (RPS) has launched a new professional liability insurance policy, designed to empower pharmacists to work confidently and deliver high-quality care, knowing they are protected.

Exclusively available to its members, the comprehensive and affordable insurance has been developed in collaboration with global professional services firm Aon.

Keep ReadingShow less
Cargo plane unloading pharmaceuticals at US airport amid tariff concerns and stockpiling

Imports jumped in particular from Ireland, the top drug exporter to the US

Pic credit: iStock

Pharma imports to US surged in March as drugmakers look to avoid tariffs

Pharmaceutical imports to the US surged in March as drugmakers stocked up ahead of potential US tariffs on their products, which have historically been exempt from such fees.

Total imports of pharmaceutical products exceeded $50 billion in the month - the equivalent of 20 per cent of all pharmaceutical imports in 2024, according to data from a U.S. Commerce Department report on Tuesday.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less